What Is TB-500?

1. TB-500 vs thymosin beta-4: what is the difference?

Thymosin beta-4 occurs naturally in the body. TB-500 generally refers to a manufactured fragment with the sequence LKKTETQ and an acetyl group attached at one end, written Ac-LKKTETQ. In Ho and colleagues’ 2012 analytical study, researchers identified this acetylated fragment in a veterinary preparation and developed a way to detect it and its metabolites in horses.

The full peptide, the unacetylated fragment and the acetylated fragment are distinct test materials. Cutting a peptide down or changing its chemistry can change how it behaves. A trial of full-length thymosin beta-4 cannot establish the same benefit or safety profile for TB-500.

The naming problem also reaches product labels. The FDA’s 2026 assessment describes different active substances being sold under the common name TB-500. A label alone cannot identify which research applies to the contents.

When reading a study, check the actual molecule, formulation and route of administration. “Thymosin beta-4 eye drops” and “TB-500 subcutaneous injection” describe different experiments. The general peptide guide explains why belonging to the same broad chemical category says little about a product’s effects.

2. How could TB-500 affect tissue repair?

Much of the rationale comes from thymosin beta-4 research. Actin helps cells maintain their shape and move. Repair also requires cells to migrate into damaged tissue, blood vessels to supply it, and connective tissue to reorganize.

In Malinda and colleagues’ 1999 rat experiment, full-length thymosin beta-4 increased coverage of skin wounds by new surface cells by 42% at day four and up to 61% at day seven compared with saline. Researchers also observed more collagen deposition and blood-vessel formation.

Those percentages describe one aspect of skin repair at specific time points. They do not mean injuries healed 61% faster, and they do not measure the recovery of a human tendon.

The fragment has a more complicated story. Rahaman and colleagues, 2024, compared TB-500 with its breakdown products in a fibroblast wound-healing assay. Only the metabolite Ac-LKKTE showed a statistically significant repair effect against the control in that assay. The authors proposed that a metabolite could account for some activity attributed to TB-500.

A metabolite is a molecule produced as the original compound breaks down. That finding makes metabolism part of the research question: which molecule reaches injured tissue, at what concentration, and for how long? A scratch closing in cultured cells cannot answer those questions for an injected product.

3. Does TB-500 help tendons? The 2026 Achilles study

Biçer and colleagues studied 32 male rats after surgically cutting and repairing an Achilles tendon. Eight rats entered each group: control, BPC-157, TB-500 or both. Treatment continued for about four weeks through injections into the abdominal cavity.

The TB-500 group had a statistically significant improvement in maximum load to failure compared with controls: the repaired tendon tolerated more force before breaking. However, only four tendons per group underwent strength testing; the other four underwent tissue examination. The combination did not provide an additional benefit.

This is an early animal result with one follow-up time point. The paper identifies a commercial supplier and catalog number but does not report a peptide sequence or independent identity testing in its methods. That limits how confidently its result can be assigned to a particular TB-500 molecule. It also cannot establish a human dose or return-to-sport timeline.

4. What do the human studies show?

Human thymosin beta-4 research is broader than human TB-500-fragment research. The trials below tested specific preparations for specific purposes. None tested the usual biohacking claim that subcutaneous TB-500 accelerates recovery from a sports injury.

The dry-eye paper is a useful example of why the outcome hierarchy matters. Its two primary measures were discomfort and inferior corneal staining at the specified follow-up visit. Both missed statistical significance. A 27% improvement in discomfort during a different assessment was a secondary finding. Reporting only that percentage would make the trial sound more conclusive than it was.

The IV study offers limited reassurance about the preparation and exposure it tested. Forty healthy volunteers observed over a short period cannot reveal rare harms or the consequences of months of use.

For the fragment itself, the FDA’s July 2026 briefing found no human clinical studies establishing effectiveness. A publication about the parent peptide does not fill that gap.

5. TB-500 vs BPC-157, and the “Wolverine stack”

BPC-157 is a different experimental peptide with 15 amino acids. Combining it with TB-500 is often called the “Wolverine stack.” There is no reliable controlled human evidence that the combination improves recovery over either compound alone.

The human report frequently cited for stacking is Lee and Padgett’s 2021 knee-pain study. Of 16 people reached by telephone, 12 had received BPC-157 alone and four had received BPC-157 plus thymosin beta-4. Eleven of the 12 single-compound recipients and three of the four combination recipients reported improvement.

The study had no placebo group, no randomized comparison and no imaging demonstration of tissue repair. Four combination recipients cannot establish whether adding thymosin beta-4 helped. The paper’s use of TB4 also does not establish equivalence to a commercial TB-500 fragment product.

For a personal recovery log, starting two compounds together creates an attribution problem. If pain falls while you also reduce training and begin rehabilitation, several explanations remain possible. More entries in a spreadsheet cannot supply the missing comparison group.

6. TB-500 dosage, half-life and injection claims

No controlled human trial establishes a TB-500 loading phase, maintenance dose or cycle length for injury recovery. Those schedules cannot be derived from a topical thymosin beta-4 trial or converted directly from a rat experiment.

The FDA review identified no human pharmacokinetic studies of TB-500 free base or acetate. A dependable human subcutaneous half-life therefore remains unestablished.

The 2024 metabolism experiment detected the breakdown product Ac-LKK in rats for up to 72 hours. Detecting a metabolite does not show that the original peptide remains active for that period, and it cannot justify a three-day injection interval in people.

Three measurements often get mixed together: how quickly the original molecule leaves circulation, how long metabolites remain detectable, and how long a biological effect lasts. A peptide half-life model needs a defensible input for the exact compound and route. An assumed half-life produces an assumed curve.

Likewise, the studies discussed here do not establish that injecting near an injury works better than injecting elsewhere, or that an oral TB-500 product delivers an effective amount to a tendon. Bioavailability has to be measured for the formulation being used.

7. TB-500 side effects and cancer concerns

There is no dependable human dataset from which to calculate TB-500 side-effect rates. Lists assigning headache, fatigue or nausea a “common” frequency need a denominator: how many people received a verified product, at what exposure, and under what monitoring?

The FDA’s safety assessment of the fragment identifies possible immune reactions related to peptide aggregation and impurities. Aggregation means molecules clumping together. A product’s identity, contaminants and tendency to aggregate can affect its safety independently of the intended peptide’s biology.

A certificate reporting a high purity percentage answers only the questions covered by its tests. It does not, by itself, establish sterility, an accurate amount per vial or clinical safety. Even a correctly identified molecule can have unknown effects in people.

Cancer concerns arise partly from full-length thymosin beta-4 experiments. In Cha, Jeong and Kleinman’s 2003 mouse melanoma study, increasing thymosin beta-4 expression was associated with greater cell migration and more blood vessels in tumors. The researchers studied tumor biology; they did not measure cancer incidence among people taking TB-500.

That experiment cannot establish that TB-500 causes cancer. It also prevents treating blood-vessel growth and cell migration as universally desirable effects. Human data do not currently quantify whether the fragment changes cancer risk, including in people with an existing malignancy.

8. Is TB-500 approved, and is it banned in sport?

TB-500 has no FDA-approved medical use as of September 20, 2026. The agency’s 2026 briefing evaluated free base and acetate forms for possible use in compounding. Advisory review and drug approval are separate processes; a committee discussion does not supply an approved treatment indication.

WADA’s Prohibited List explicitly includes thymosin beta-4 and derivatives such as TB-500 under S2, with prohibition applying both in and out of competition. A ban is not evidence that the compound improves athletic performance, and taking it only during rehabilitation does not remove the anti-doping restriction.

9. What would convincing recovery evidence look like?

For biohackers following this research, the useful next study would identify the peptide chemically, compare it with placebo alongside the same rehabilitation program, and measure function as well as symptoms. Relevant outcomes include tendon strength, validated activity scores, return to sport and reinjury over longer follow-up.

When reading a recovery report, record the diagnosis, starting function, changes in training load, rehabilitation and other treatments alongside the symptom timeline. A fall in pain is worth documenting. On its own, it cannot tell you that a damaged tendon has regained its strength.

10. TB-500 FAQ

• What is TB-500 used for?

  TB-500 is marketed for tendon, muscle and wound recovery. These uses remain experimental. Animal and laboratory findings give researchers reasons to investigate it, but controlled human evidence has not established faster recovery from sports injuries.

• Is TB-500 the same as thymosin beta-4?

  The names are often mixed together. Chemically, TB-500 usually means Ac-LKKTETQ, a seven-amino-acid fragment. Full-length thymosin beta-4 contains 43 amino acids. A paper on one molecule does not establish the effects of the other.

• Does TB-500 heal tendons?

  A 2026 rat Achilles study reported improved tendon strength with material labeled TB-500. It used surgically repaired tendons, a short follow-up and a small sample. Human trials have not established tendon healing or an earlier safe return to sport.

• What are the side effects of TB-500?

  Reliable human side-effect rates are unavailable. FDA identifies possible immune reactions associated with peptide aggregation and impurities. Short studies of full-length thymosin beta-4 cannot establish the fragment's long-term safety.

• What is the recommended TB-500 dosage?

  There is no approved or clinically validated dose for injury recovery. Loading phases, maintenance schedules and cycle lengths shared online have not been established by controlled human trials of the fragment.

• What is the half-life of TB-500?

  A dependable human half-life for subcutaneous TB-500 has not been established. Detection of a breakdown product for 72 hours in rats does not mean the active peptide lasts 72 hours in people.

• Does TB-500 cause cancer?

  Human data do not establish whether TB-500 changes cancer risk. Experiments involving full-length thymosin beta-4 and tumor biology raise questions, but cannot quantify the risk from the TB-500 fragment.

• Does stacking TB-500 with BPC-157 work better?

  No reliable controlled human comparison establishes an advantage. A small knee-pain report included four people receiving BPC-157 plus thymosin beta-4; three reported improvement. It could not isolate the contribution of either compound.

• Is TB-500 FDA-approved or allowed in tested sport?

  TB-500 has no FDA-approved medical use as of September 20, 2026. A compounding committee review is separate from drug approval. WADA prohibits thymosin beta-4 and derivatives including TB-500 at all times under S2.

11. Sources